Radiodermatitis Market Overview
The global radiodermatitis market report analyses the shares, size, recent trends, future market outlook, and competitive intelligence. Radiodermatitis a condition caused by radiation therapy used for cancer treatment is on the rise. Demand from hospital pharmacies and pharmacy stores in the USA is rising. The competitive rivalry intensifies with CIVCO Radiotherapy, Acelity, and others active in the market.
Radiodermatitis also known as radiation dermatitis, is a condition caused by radiation therapy used for cancer treatment. Radiodermatitis occurs in approximately 95% of patients receiving radiation therapy, especially patients with breast cancer, head & neck cancer, skin cancer, lung cancer, or sarcoma. Cumulative daily doses of radiation to the treatment field or target site on the body inhibit normal skin repopulation and fade skin integrity at and around the radiation field.
Radiodermatitis Market Scope
| Metrics | Details |
| Market CAGR | 4.1% |
| Segments Covered | By Product, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample :-Click here
Radiodermatitis Market Dynamics and Trends
The global radiodermatitis market growth is driven by the increase in the prevalence of cancer and the rise in the adoption of radiotherapy for treatment globally. In addition, the increase in the geriatric population further fuels the growth of the radiodermatitis market.
The rising prevalence of cancer incidence across the globe and growing co-morbid conditions are expected to drive growth in the forecast period
According to the WHO, the number of new cancer cases is expected to rise to 22 million by 2032, and 9.6 million deaths are estimated in the year 2018. As per International Agency for Research on Cancer (IARC), the global cancer burden increases with 18.1 million cases and estimated new cases each year. In addition, the rate of certain types of cancers such as breast cancer and head and neck cancer is projected to escalate. This is attributable to faulty lifestyle factors such as obesity or breast cancer. Moreover, the aforementioned cancers are treated with radiation at the site. Hence, patients suffering from these cancers are more likely to develop radiation-induced dermatitis. Therefore, the overall spiral in cancer cases coupled with a surge in specific cancers due to faulty lifestyles is likely to propel the radiodermatitis market. As per WHO, statistics, growing tobacco consumption and alcohol abuse accounts for 40% of the cancer burden across European countries. Amongst this 20% of cancer lead to deaths in the European region.
Increasing focus on research to find a standard pertinent treatment expected to drive the market growth
Increasing focus on research to find a standard pertinent treatment is also expected to propel the radiodermatitis market. The lack of standard care products in the market makes it a highly opportune condition for players to set their innovative product ideas on the path of commercial success. Radiodermatitis is a skin condition that affects cancer patients undergoing radiation therapy or a combination of chemotherapy and radiation therapy.
The rise in the number of people suffering from diabetes and obesity rapidly puts them at an added risk of developing cancer. This factor is likely to drive the need for radiation therapy and boost radiodermatitis incidences. Old age and obesity are also risk factors for cancer, which is likely to rise the demand for radiodermatitis drugs. According to the CDC (Centers for Disease Control), in the year 2018, diabetes cases have risen to 34.2 million, which is likely to grow in the world by 2030. This escalation will indicate that there is a larger pool of patients likely to develop cancer and they would have a higher chance of radiation-induced skin damage due to co-morbid conditions.
Higher costs of the therapeutics are likely to hamper the market growth
The burden of the cost of cancer treatment is a concern in developing nations, where the high cost of therapy leads to constraints on financial resources. Hence, the high cost of products, especially dressings such as honey-impregnated dressings and silicone dressings, is likely to restrain the market. Moreover, the availability of low-cost locally-manufactured dressings in emerging economies is expected to hamper the growth of branded and expensive dressings
Radiodermatitis Market Segmentation Analysis
The topical segment is expected to grow at the fastest CAGR during the forecast period (2026-2033)
The topical segment is expected to dominate the market owing to their ease of application, easy availability, less systemic absorption, cost-efficiency, and reduced side effects accelerating the adoption rate among consumers in the future. Corticosteroids are the major sub-segment in tropical products. Corticosteroids are a class of steroid hormones produced in the adrenal cortex. They are involved in a wide range of physiologic systems such as stress and immune responses, the regulation of inflammation, carbohydrate metabolism, and protein catabolism. Corticosteroids can be administered orally, intravenously, or topically and are used to treat a variety of conditions. Drugs in this class include dexamethasone, methylprednisone, prednisone, hydrocortisone, mometasone, betamethasone, and fludrocortisone. Topical use of specific corticosteroids has been examined for their efficacy in treating radiodermatitis, skin reactions, and mucositis, and in the prevention of bleeding.
Hydrophilic creams are a traditional oil-in-water emulsion containing petrolatum and propylene glycol. It is easy to spread and water-washable. Hydrophilic creams can accept some water to create a thinner base for compounding topical lotion preparations. This medication is used as a moisturizer to treat or prevent dry, rough, scaly, itchy skin and minor skin irritations. Emollients are substances that soften and moisturize the skin and decrease itching and flaking.
The hospital pharmacy is expected to dominate the radiodermatitis market during the forecast period
The hospital pharmacies held the largest share of the radiodermatitis market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, a growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.
Radiodermatitis Market Geographical Share
North American region holds the largest market share global radiodermatitis market
North American region is dominating the global radiodermatitis market and accounted for the largest market share in 2020. The expanding cancer patient base present across this region serves as a key contributor toward the substantial share captured by this region. In addition, extensive collaborations undertaken by key players for increasing their product portfolio expansion capabilities are responsible for the greater share captured by this region. Moreover, the development of assessment tools by various organizations such as the Radiation Therapy Oncology Group (RTOG) and National Cancer Institute (NCI) used to identify degrees of skin reactions and to determine the severity of radiation dermatitis are propelling demand for topical creams, gels, and dressings. A growing number of clinical research and development activities for developing innovative products used to treat adverse effects of radiation therapies will further expand the product pipeline over the forecast years.
Radiodermatitis Market Companies and Competitive Landscape
The radiodermatitis market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include CIVCO Radiotherapy, Acelity, Smith & Nephew, Molnlycke Health Care, Derma Sciences, Stratpharma, ConvaTec, 3M, BMG Pharma, and Alliqua Biomedical among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiodermatitis market globally.
CIVCO Radiotherapy
Overview: CIVCO Radiotherapy has over 35 years of experience in the radiation oncology industry and offers patient-centric radiotherapy solutions. These solutions include couch tops and overlays for linear accelerators and imaging systems, advanced patient immobilization solutions, robotic patient positioning, advanced fiducial markers, and immobilization/positioning equipment and consumables.
Product Portfolio: The Company’s portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
Radiodermatitis Market Key Developments
July 2026: VasoDynamics Ltd received positive feedback from China’s NMPA following a Pre-IND meeting for Derm1 (NG12-2), its topical medicine designed to prevent or reduce radiodermatitis in head-and-neck radiotherapy patients. The feedback provided guidance on the Chinese clinical-development requirements and regulatory pathway, supporting planned global development.
- June 2026: VasoDynamics Ltd completed a Scientific Advisory meeting with the UK MHRA for Derm1 (NG12-2). The discussion covered the proposed Phase 3 clinical-study design and approval pathway, providing regulatory guidance for advancing the radiodermatitis-prevention program toward commercialization.
- March 2026: Devonian Health Group Inc. identified its Thykamine™ radiodermatitis-prevention pivotal clinical study as the company’s first priority, continuing preparations for a multicenter study evaluating the topical formulation in patients receiving radiotherapy for breast cancer.
The global radiodermatitis market report would provide access to approximately 45+ market data tables, 40+ figures, and 180 pages.
Why Choose DataM?
- Technological Innovations: Explores advancements in radiodermatitis prevention, assessment, and treatment, including topical corticosteroids, barrier and moisturizing formulations, wound-care approaches, photobiomodulation, and emerging supportive-care technologies, with attention to improving symptom management, skin protection, healing, and quality of life for patients receiving radiotherapy.
- Product Performance & Market Positioning: Evaluates radiodermatitis management products and therapies based on clinically relevant parameters such as prevention of radiation-induced skin damage, reduction of erythema, dryness, pain, itching, desquamation, wound severity, treatment tolerability, healing support, ease of application, and suitability across different radiotherapy settings, highlighting how leading products differentiate through clinical evidence, safety, and patient convenience.
- Real-World Evidence: Highlights the use of radiodermatitis prevention and treatment strategies among patients undergoing radiotherapy for breast, head and neck, skin, and other cancers, demonstrating their role in reducing treatment-related skin reactions, supporting skin integrity, improving patient comfort, and helping patients maintain continuity of radiotherapy when clinically appropriate.
- Market Updates & Industry Changes: Tracks key developments such as clinical studies of radiodermatitis prevention and treatment approaches, new topical and wound-care products, photobiomodulation research, guideline and supportive-care updates, regulatory developments, strategic collaborations, and increasing adoption of evidence-based skin-care protocols across oncology centers and radiotherapy facilities.
- Competitive Strategies: Analyzes how leading companies expand through product innovation, clinical research, regulatory approvals, strategic collaborations, portfolio expansion, acquisitions, and partnerships with oncology and healthcare providers to strengthen their position in the radiodermatitis management market.
- Pricing & Market Access: Explains pricing variations based on product formulation, active ingredients, treatment duration, dosage or application requirements, clinical positioning, product format, and distribution channel, along with market access through hospitals, oncology centers, pharmacies, specialty healthcare providers, and online healthcare channels.
- Market Entry & Expansion: Identifies growth opportunities driven by the increasing use of radiotherapy, growing cancer incidence, greater awareness of radiation-induced skin toxicity, demand for supportive oncology care, and advances in skin-protection and wound-management technologies, while outlining strategies such as evidence-based product development, clinical partnerships, regional regulatory approvals, healthcare-provider engagement, and expansion into emerging oncology markets.
Target Audience
- Oncology & Radiation Oncology Centers
- Radiation Oncologists & Cancer Care Providers
- Radiodermatitis Treatment & Wound-Care Product Manufacturers
- Pharmaceutical & Specialty Dermatology Companies
- Medical Device & Photobiomodulation Technology Companies
- Hospitals & Cancer Treatment Facilities
- Distributors & Specialty Healthcare Providers
